


## 8-Isoprostaglandin F2 $\alpha$ -<sup>13</sup>C<sub>5</sub>

<b>Cat. No.:</b>	HY-113209S2
<b>Molecular Formula:</b>	C <sub>15</sub> <sup>13</sup> C <sub>5</sub> H <sub>27</sub> O <sub>5</sub>
<b>Molecular Weight:</b>	352.39
<b>Target:</b>	Endogenous Metabolite; Isotope-Labeled Compounds
<b>Pathway:</b>	Metabolic Enzyme/Protease; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	8-Isoprostaglandin F2 $\alpha$ - <sup>13</sup> C <sub>5</sub> is <sup>13</sup> C labeled 8-Isoprostaglandin F2 $\alpha$ (HY-113209). 8-Isoprostaglandin F2 $\alpha$ is an isoprostane produced by the non-enzymatic peroxidation of arachidonic acid in membrane phospholipids. 8-Isoprostaglandin F2 $\alpha$ is present in human plasma in two distinct forms - esterified in phospholipids and as the free acid. 8-Isoprostaglandin F2 $\alpha$ is a weak TP receptor agonist in vascular smooth muscle.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA